ASMB ▼ -3.6% - Assembly Biosciences, Inc. $ASMB - Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program Assembly Biosciences exercised its U.S. profit-share option with Gilead for an HSV helicase-primase inhibitor program, a move that shifts the company's financial participation in the program but may have raised investor concerns about dilution or reduced near-term revenue upside, contributing to the 3.6% decline. 08-SEP-2026 04:00 PM ET